迪威迅(300167.SZ)延期回覆深交所問詢函
格隆匯1月9日丨迪威迅(300167.SZ)公佈,公司董事會於2020年1月7日收到深圳證券交易所創業板管理部下發的《關於對深圳市迪威迅股份有限公司的問詢函》(創業板問詢函【2020】第2號)(“問詢函”)。
公司收到問詢函後,積極組織各相關方、律師、會計師共同對問詢函中涉及的問題進行逐項落實和回覆。由於此次問詢函的回覆內容尚需進一步完善,目前相關工作正在進行中,經向深圳證券交易所申請,同意公司延期回覆。公司將積極推進問詢函的回覆工作,預計將於2020年1月13日前完成回覆報送深圳證券交易所,並及時履行相關信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.